Home Overview Press Room Blog Publications For Students about us

About Patents, Other Intellectual Property & Human Biotechnology

Human biotechnology is both constrained and catalyzed by intellectual property law, which regulates who can use certain information, ideas, and processes. Patents—one form of intellectual property—give the holder an exclusive right to produce and sell an invention.

While patents provide an incentive to inventors, they can also inhibit information flow. Their management has a tremendous impact on how biotechnologies are developed, and who benefits from them.

In the United States, the development of biotechnology has been dramatically influenced by two developments in 1980 that greatly increased the incentives for the commercialization of the life sciences. Congress passed the Bayh-Dole Act, which reformed how inventions from federally-funded research are managed. The same year, the Supreme Court ruled in Diamond v. Chakrabarty that living things, including genes, could be patented.

Blame bad incentives for bad scienceby Bethany BerkshireScienceNewsOctober 21st, 2016The publish-or-perish culture promotes high-impact papers with novel findings, ultimately leading to sloppy, irreproducible, and sometimes unethical practices.
Just What We Need: Slicker Infertility Marketingby Gina Maranto, Biopolitical Times guest contributorOctober 21st, 2016A serial tech entrepreneur launches a new start-up called Prelude with a hipster-chic website downplaying the many unknowns of egg freezing.
Crispr’s IPO doesn’t hit its targetby Robert WeismanThe Boston GlobeOctober 19th, 2016CRISPR Therapeutics' public offering raises half that of its rivals Editas & Intellia -- a sign that the market may be pulling back on genome editing stocks.
California stem cell agency approves $30 million to fast-track clinical trialsby David JensenThe Sacramento BeeOctober 19th, 2016Dubbed the new “pitching machine,” CIRM on Wednesday completed creation of a $30 million effort to dramatically speed up FDA approval of stem cell therapies.
Don’t Miss This: The Story of CRISPR Told in a Comicby Kayla TolentinoOctober 6th, 2016Illustrator Andy Warner helps to break down the complexities of the still unraveling CRISPR gene editing story in his recent piece "Bad Blood."
Dramatic Twists Could Upend Patent Battle Over CRISPR Genome-Editing Methodby Jon CohenScience MagazineOctober 5th, 2016The Broad Institute requests to separate 4 of its issued patents from the larger case, which could permit "a way for both sides to walk away with a little IP in their pockets."
Titanic Clash Over CRISPR Patents Turns Uglyby Heidi LedfordNature September 21st, 2016The billion-dollar patent battle over CRISPR-Cas9 gene editing has moved from scientific minutiae to accusations of impropriety.
Hacking life: Scientists ‘recode’ DNA in step toward lab-made organismsby Sharon BegleySTATAugust 18th, 2016It may not be long before scientists assemble genomes of higher organisms, as George Church proposed to do for the human genome.
In CRISPR Fight, Co-Inventor Says Broad Institute Misled Patent Officeby Antonio RegaladoMIT Technology ReviewIs an email between competing researchers a smoking gun in the billion-dollar battle over patent rights for gene editing?
CRISPR patent fight: The legal bills are soaringby Sharon BegleySTATAugust 16th, 2016Editas has already spent $10.9 million in 2016. Many in the CRISPR field wonder privately why the Broad Institute and UC Berkeley have not reached a settlement.
Displaying 1-10 of 404  
Next >> 
Last Page » 
« Show Complete List » 


home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760